These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 23840000)
1. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066 [TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study. Yang QJ; Xiang BX; Song MH; Yang CY; Liang JH; Xie YL; Zuo XC Pharmacotherapy; 2024 Aug; 44(8):631-641. PubMed ID: 39046197 [TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553 [TBL] [Abstract][Full Text] [Related]
5. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846 [TBL] [Abstract][Full Text] [Related]
6. Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study. Dalfino L; Puntillo F; Ondok MJ; Mosca A; Monno R; Coppolecchia S; Spada ML; Bruno F; Brienza N Clin Infect Dis; 2015 Dec; 61(12):1771-7. PubMed ID: 26354965 [TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B? Zavascki AP; Nation RL Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859 [TBL] [Abstract][Full Text] [Related]
8. Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury. Pike M; Saltiel E J Pharm Pract; 2014 Dec; 27(6):554-61. PubMed ID: 25237156 [TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity associated with intravenous colistin in critically ill patients. Doshi NM; Mount KL; Murphy CV Pharmacotherapy; 2011 Dec; 31(12):1257-64. PubMed ID: 22122186 [TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Hartzell JD; Neff R; Ake J; Howard R; Olson S; Paolino K; Vishnepolsky M; Weintrob A; Wortmann G Clin Infect Dis; 2009 Jun; 48(12):1724-8. PubMed ID: 19438394 [TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin. Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744 [TBL] [Abstract][Full Text] [Related]
13. Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS). Truong CB; Durham SH; Qian J Expert Opin Drug Saf; 2021 May; 20(5):603-609. PubMed ID: 33573405 [No Abstract] [Full Text] [Related]
14. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. Phe K; Shields RK; Tverdek FP; Aitken SL; Guervil DJ; Lam WM; Musgrove RJ; Luce AM; Tam VH J Antimicrob Chemother; 2016 Dec; 71(12):3585-3587. PubMed ID: 27543655 [TBL] [Abstract][Full Text] [Related]
15. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS Diagn Microbiol Infect Dis; 2009 Dec; 65(4):431-4. PubMed ID: 19733029 [TBL] [Abstract][Full Text] [Related]
16. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974 [TBL] [Abstract][Full Text] [Related]
17. Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins. Aysert-Yildiz P; Özgen-Top Ö; Şentürk AF; Kanik S; Özger HS; Dizbay M BMC Infect Dis; 2024 Aug; 24(1):862. PubMed ID: 39187812 [TBL] [Abstract][Full Text] [Related]
18. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction. Turkoglu M; Dizbay M; Ciftçi A; Aksakal FN; Aygencel G Int J Antimicrob Agents; 2012 Feb; 39(2):142-5. PubMed ID: 22115538 [TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium. Hassan MM; Gaifer Z; Al-Zakwani IS Int J Clin Pharm; 2018 Apr; 40(2):444-449. PubMed ID: 29542034 [TBL] [Abstract][Full Text] [Related]
20. Colistin nephrotoxicity increases with age. Balkan II; Dogan M; Durdu B; Batirel A; Hakyemez IN; Cetin B; Karabay O; Gonen I; Ozkan AS; Uzun S; Demirkol ME; Akbas S; Kacmaz AB; Aras S; Mert A; Tabak F Scand J Infect Dis; 2014 Oct; 46(10):678-85. PubMed ID: 25073536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]